Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.
The Idec Pharmaceuticals Corporation patent solves the following problem:
The immune system is capable of producing two types of antigen-specific response to foreign antigens. Cell-mediated immunity is the term used to refer to effector functions of the immune system mediated by T lymphocyte. Humoral immunity is the term used to refer to the production of antigen-specific antibody in the B lymphocyte. It has long been appreciated that the development of humoral immunity against most antigens requires not only antibody-producing B lymphocytes but also the involvement of helper T (called th) lymphocyte. (Mitchison, EUR J. Immunol, 1: 18-25 (1971); Claman and Chaperon, Transplant Pin, 1: …… 92-119 (1969); Katz et al, Proc Natl Acad Sci USA, 70 : 2624-2629 (1973); Reff et al, Nature, 226: 1257-1260 (1970)). Some signal, or assistance given by Th cells in response to stimulation by Thymus-dependent (called TD) antigens. While some B lymphocyte help mediated by soluble molecules released by Th cells (for instance lymphokines such as IL-4 and IL-5), activation of B cells also requires a contact-dependent interaction between cells B cells and th. (Hirohata et al, J. Immunol, 140: 3736-3744 (1988); Bartlett et al, J. Immunol, 143: 1745-1765 (1989)). This indicates that B cell activation involves an obligatory interaction between cell surface molecules on B cells and cells th. Such an interaction further supported by the observation that isolated plasma membranes of activated T cells can provide helper functions necessary for B cell activation. (Brian, Proc Natl Acad Sci USA, 85: 564-568 (1988); Hodgkin et al, J. Immunol, 145: …… 2025-2034 (1990); Noelle et al, J. Immunol, 146 : 1118-1124 (1991)).
Our analysis of this patent is as follows:
Idec Pharmaceuticals Corporation’s patent US 6440418 B1 deals with Methods of treating autoimmune diseases with gp39-specific antibodies.
The present invention is directed to humanized antibodies that bind to human GP39 and their use as therapeutic agents. These humanized antibody particularly useful for the treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy and gene therapy.
The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.